StockData

Ionis Pharmaceuticals vs Kiniksa Pharmaceuticals International

IONS and KNSA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How IONS and KNSA compare

Kiniksa Pharmaceuticals International is the larger company, worth 3.3 times as much as Ionis Pharmaceuticals ($14.9B against $4.5B).

Kiniksa Pharmaceuticals International grew revenue faster over the last twelve months (58.2% versus −7.4% for Ionis Pharmaceuticals).

Kiniksa Pharmaceuticals International keeps more of each dollar of sales as profit, with a net margin of 11.6% compared with −64.7% at Ionis Pharmaceuticals.

Kiniksa Pharmaceuticals International scores higher on the StockData Score (14 against 4 for Ionis Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricIONSKNSA
Size and price
Market cap$4.5B$14.9B
Share price$26.96$95.11
Change, 1 year−62.3%136%
Change, 5 years−7.2%716%
Beta (5Y)0.600.15
Employees1,402366
StockData Score
Total score414 (better)
Valuation score1 (better)0
Growth score24 (better)
Performance score04 (better)
Health score16 (better)
Dividend score00
Valuation
P/E–73.2×
P/S5.1× (better)15.8×
P/B10.2× (better)21.0×
EV/EBITDA–109×
P/FCF–75.8×
FCF yield−12.5%1.3% (better)
Fair value$27.86$16.72
Margin of safety3.2% (better)−469%
Growth
Revenue growth (TTM)−7.4%58.2% (better)
Revenue growth, 5Y average5.3%–
Net income growth (TTM)–205%
EPS growth (TTM)–189%
Profitability
Gross margin98.2% (better)90.2%
Operating margin−68.0%13.8% (better)
Net margin−64.7%11.6% (better)
FCF margin−64.2%20.8% (better)
Return on equity−105%17.6% (better)
Return on invested capital–60.2%
Financial health
Debt / equity–0.00
Interest coverage−31.6×–
Current ratio7.89 (better)3.91
Altman Z-score0.2334.40 (better)
Piotroski F-score48 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions108%29.9%
Held by insiders0.81%5.1%
Insider net buying, 12 months−$114M (better)−$122M
Superinvestors holding1–
Short interest, % of float12.8%2.9%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.